Cochrane · systematic review · CD010623
Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions
Song, H, Zhu, J, Lu, D · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 25%Low 3 · 75%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Proton pump inhibitor compared with control for gastric pre‐malignant lesions
Population: people with pre‐malignant lesions
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with worsening scores in corporal atrophy Proton pump inhibitor vs control | OR 1.5 [0.59, 3.8] | 4 studies · 1070 participants | Low Downgraded: risk of bias, imprecision |
Number of participants with worsening scores in corporal intestinal metaplasia Proton pump inhibitor vs control | OR 1.46 [0.43, 5.03] | 5 studies · 1408 participants | Low Downgraded: risk of bias, imprecision |
Increase in the number of participants with simple (diffuse) hyperplasia after treatment Proton pump inhibitor vs control | OR 5.01 [1.54, 16.26] | 6 studies · 1705 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Increase in the number of participants with linear/micronodular (focal) hyperplasia, comparing final biopsies with baseline biopsies Proton pump inhibitor vs control | OR 3.98 [1.31, 12.16] | 6 studies · 1705 participants | Low Downgraded: risk of bias, imprecision |